MedEvidence Articles podcast

5:03

Medical treatments are shifting from broad approaches to precise genetic targeting, especially for finicky diseases like Alzheimer's dementia. While many past efforts focused on amyloid β plaques, new research is exploring genetic regulators like APP, which influences amyloid levels, and KDM5, an enzyme linked to memory and cognition. Clinical trials are testing drugs that could balance these proteins and potentially slow cognitive decline at its root. Tune in this week for a deep look into the genetics of Alzheimer's Share with a friend. Rate, Review, and Subscribe to MedEvidence! Articles to be notified when new episodes are released. Follow us on Social Media: Facebook Instagram Twitter LinkedIn Tiktok Youtube For more great content, including discussions by physicians and clinical research experts, check out the MedEvidence! podcast. www.MedEvidence.com Thank you for listening! References: Bandyopadhyay, S., & Rogers, J. T. (2014). Alzheimer's disease therapeutics targeted to the control of amyloid precursor protein translation: maintenance of brain iron homeostasis. Biochemical pharmacology, 88(4), 486-494. https://pmc.ncbi.nlm.nih.gov/articles/PMC4064675/ Kim, C. K., et al. (2022). Alzheimer’s disease: key insights from two decades of clinical trial failures. Journal of Alzheimer's Disease, 87(1), 83-100. https://content.iospress.com/articles/journal-of-alzheimers-disease/jad215699 Maccecchini, M. L., et al. (2012). Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans. Journal of Neurology, Neurosurgery & Psychiatry, 83(9), 894-902. https://jnnp.bmj.com/content/83/9/894.short Delport, A., & Hewer, R. (2022). The amyloid precursor protein: A converging point in Alzheimer’s disease. Molecular Neurobiology, 59(7), 4501-4516. https://link.springer.com/article/10.1007/s12035-022-02863-x Cahill, C. M., et al. (2009). Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases. Biochimica et Biophysica Acta (BBA)-General Subjects, 1790(7), 615-628. https://pmc.ncbi.nlm.nih.gov/articles/PMC3981543/ Kisby, B., et al. (2019). Alzheimer’s disease and its potential alternative therapeutics. Journal of Alzheimer's disease & Parkinsonism, 9(5). https://pmc.ncbi.nlm.nih.gov/articles/PMC6777730/ Collins, B. E., et al. (2019). Broad domains of histone 3 lysine 4 trimethylation are associated with transcriptional activation in CA1 neurons of the hippocampus during memory formation. Neurobiology of learning and memory, 161, 149-157. https://pmc.ncbi.nlm.nih.gov/articles/PMC6541021/ Kandel, E. R., et al (Eds.). (2000). Principles of neural science (Vol. 4). New York: McGraw-hill. Gehling, V. S., et al. (2016). Identification of potent, selective KDM5 inhibitors. Bioorganic & medicinal chemistry letters, 26(17), 4350-4354. https://www.sciencedirect.com/science/article/abs/pii/S0960894X16307399 Liu, X., & Secombe, J. (2015). The histone demethylase KDM5 activates gene expression by recognizing chromatin context through its PHD reader motif. Cell reports, 13(10), 2219-2231. https://pmc.ncbi.nlm.nih.gov/articles/PMC4684901/ Zhou, J. (2022). Gene-expression control in early and late-onset dementia. [Doctoral dissertation, Georg-August-Universität Göttingen]. http://dx.doi.org/10.53846/goediss-9465…

1
Digging Up the Truth About Potatoes 5:45

13 days ago5:45

5:45

This St. Patrick's Day we explore the history, nutritional profile, and potential health benefits of potatoes. Potatoes are a major global food staple, providing significant calories worldwide. Though often criticized for their high glycemic index (GI), different cooking methods, particularly chilling after cooking, can increase resistant starches, which improve gut health and reduce blood sugar impact. Potatoes also have a high satiety index, making them more filling than many other foods. While long-term clinical studies are needed, current epidemiological data suggest that potatoes are not linked to negative health outcomes—unless consumed as french fries. Share with a friend. Rate, Review, and Subscribe to MedEvidence! Articles to be notified when new episodes are released. Follow us on Social Media: Facebook Instagram Twitter LinkedIn Tiktok Youtube For more great content, including discussions by physicians and clinical research experts, check out the MedEvidence! podcast. www.MedEvidence.com Thank you for listening! References: Sagili, V. S., et al. (2022). The glycemic index and human health with an emphasis on potatoes. Foods, 11(15), 2302. https://pmc.ncbi.nlm.nih.gov/articles/PMC9368276/ Robertson, T. M., et al. (2018). Starchy carbohydrates in a healthy diet: the role of the humble potato. Nutrients, 10(11), 1764. https://www.mdpi.com/2072-6643/10/11/1764?gsid=ba4def2d-71eb-4462-a8ac-9fda238e474b Atkinson, F. S., et al. (2021). International tables of glycemic index and glycemic load values 2021: a systematic review. The American journal of clinical nutrition, 114(5), 1625-1632. https://www.sciencedirect.com/science/article/pii/S0002916522004944 Fuentes-Zaragoza, E., et al. (2010). Resistant starch as functional ingredient: A review. Food Research International, 43(4), 931-942. https://www.sciencedirect.com/science/article/abs/pii/S0963996910000621 Raatz, S. K., et al. (2016). Resistant starch analysis of commonly consumed potatoes: Content varies by cooking method and service temperature but not by variety. Food Chemistry, 208, 297-300. https://pubmed.ncbi.nlm.nih.gov/27132853/ Borch, D., et al. (2016). Potatoes and risk of obesity, type 2 diabetes, and cardiovascular disease in apparently healthy adults: a systematic review of clinical intervention and observational studies12. The American journal of clinical nutrition, 104(2), 489-498. https://ajcn.nutrition.org/article/S0002-9165(22)04562-2/fulltext McGill, C. R., et al. (2013). The role of potatoes and potato components in cardiometabolic health: A review. Annals of medicine, 45(7), 467-473. https://www.tandfonline.com/doi/full/10.3109/07853890.2013.813633…

1
What are Cluster Headaches? 6:28

20 days ago6:28

6:28

In this week's episode, we discuss cluster headaches, one of the most severe pain conditions known. This rare condition affects about one in a thousand people with excruciating, clockwork-like attacks can last for weeks or months, with few effective treatment options. In this episode, we break down the causes, triggers, and latest research on cluster headaches, from abortive therapies like oxygen and triptans to emerging neuromodulation treatments. Share with a friend. Rate, Review, and Subscribe to MedEvidence! Articles to be notified when new episodes are released. Follow us on Social Media: Facebook Instagram Twitter LinkedIn Tiktok Youtube For more great content, including discussions by physicians and clinical research experts, check out the MedEvidence! podcast. www.MedEvidence.com Thank you for listening! References: Actual Patient Testimony. (February 3, 2025). As interviewed by the author. May, A., Schwedt, T. J., Magis, D., Pozo-Rosich, P., Evers, S., & Wang, S. J. (2018). Cluster headache. Nature reviews Disease primers, 4(1), 1-17. https://www.nature.com/articles/nrdp20186 International Headache Society. (2018). 3.1. Cluster headache. IHS Classification ICHD-3. https://ichd-3.org/3-trigeminal-autonomic-cephalalgias/3-1-cluster-headache/ Rozen, T. D., & Fishman, R. S. (2012). Cluster headache in the United States of America: demographics, clinical characteristics, triggers, suicidality, and personal burden. Headache: The Journal of Head and Face Pain, 52(1), 99-113. https://pubmed.ncbi.nlm.nih.gov/22077141/ Wilbrink, L. A., de Coo, I. F., Doesborg, P. G., Mulleners, W. M., Teernstra, O. P., Bartels, E. C., ... & Rasche, D. (2021). Safety and efficacy of occipital nerve stimulation for attack prevention in medically intractable chronic cluster headache (ICON): a randomised, double-blind, multicentre, phase 3, electrical dose-controlled trial. The Lancet Neurology, 20(7), 515-525. https://pubmed.ncbi.nlm.nih.gov/34146510/ Pringsheim, T. (2002). Cluster headache: evidence for a disorder of circadian rhythm and hypothalamic function. Canadian journal of neurological sciences, 29(1), 33-40. https://doi.org/10.1017/S0317167100001694 Riesenberg, R., Gaul, C., Stroud, C. E., Dong, Y., Bangs, M. E., Wenzel, R., ... & Oakes, T. M. (2022). Long-term open-label safety study of galcanezumab in patients with episodic or chronic cluster headache. Cephalalgia, 42(11-12), 1225-1235. https://pubmed.ncbi.nlm.nih.gov/35633025/ Goadsby, P. J., de Coo, I. F., Silver, N., Tyagi, A., Ahmed, F., Gaul, C., ... & Ferrari, M. D. (2018). Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: a randomized, double-blind, sham-controlled ACT2 study. Cephalalgia, 38(5), 959-969. https://journals.sagepub.com/doi/10.1177/0333102417744362 Silberstein, S. D., Mechtler, L. L., Kudrow, D. B., Calhoun, A. H., McClure, C., Saper, J. R., ... & ACT1 Study Group. (2016). Non–invasive vagus nerve stimulation for the acute treatment of cluster headache: findings from the randomized, double‐blind, sham‐controlled ACT1 study. Headache: The Journal of Head and Face Pain, 56(8), 1317-1332. https://pubmed.ncbi.nlm.nih.gov/27593728/…

1
Alzheimer’s Anxiety: What’s Normal, What’s Not, and When to Act 3:55

27 days ago3:55

3:55

Forgetting a name or misplacing your keys can be frustrating, but when does memory loss signal something more serious? In this episode, we explain the key differences between normal aging and Alzheimer’s disease. We break down how doctors diagnose Alzheimer’s, the role of biomarkers, and why early detection is crucial for those considering clinical trials. Share with a friend. Rate, Review, and Subscribe to MedEvidence! Articles to be notified when new episodes are released. Follow us on Social Media: Facebook Instagram Twitter LinkedIn Tiktok Youtube For more great content, including discussions by physicians and clinical research experts, check out the MedEvidence! podcast. www.MedEvidence.com Thank you for listening! References: Koren, MJ. Toenjes, S. & McKormick, M. (13 April, 2022). Is it Alzheimer's or something else? In MedEvidence! Truth Behind the Data [Podcast]. https://www.buzzsprout.com/admin/1926091/episodes/10248455-is-it-alzheimer-s-or-something-else-ep-11 National Institute on Aging. (8 December, 2022) How is Alzheimer's disease diagnosed? U.S. Department of Health and Human Services, National Institutes of Health . https://www.nia.nih.gov/health/alzheimers-symptoms-and-diagnosis/how-alzheimers-disease-diagnosed Jack Jr, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., ... & Carrillo, M. C. (2024). Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimer's & Dementia, 20 (8), 5143-5169. https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.13859…

1
New Research on Heart Failure: Understanding IL-6 and Inflammation 4:38

5 weeks ago4:38

4:38

This week, we talk about one of the big contributors to heart failure: inflammation. Heart failure affects millions and comes in two main types: HFrEF (weakened pumping) and HFpEF (thickened, stiff walls). While conditions like high blood pressure and diabetes contribute, chronic inflammation—driven in part by Interleukin 6 (IL-6)—plays a major role. IL-6 causes muscle damage, fibrosis, and worsens other diseases. Researchers are developing monoclonal antibodies to regulate IL-6, offering a potential breakthrough technology in reducing inflammation and improving heart health. Share with a friend. Rate, Review, and Subscribe to MedEvidence! Articles to be notified when new episodes are released. Follow us on Social Media: Facebook Instagram Twitter LinkedIn Tiktok Youtube For more great content, including discussions by physicians and clinical research experts, check out the MedEvidence! podcast. www.MedEvidence.com Thank you for listening! References: Martin, S. S., et al. (2024). 2024 heart disease and stroke statistics..., 149(8), e347-e913. https://www.ahajournals.org/doi/10.1161/CIR.0000000000001209 Oktay, A. A., et al. (2013). The emerging epidemic of heart failure with preserved ejection fraction. Current heart failure reports, 10, 401-410. https://pmc.ncbi.nlm.nih.gov/articles/PMC3870014/ Centers for Disease Control. (15 May, 2024). About Heart Failure. U.S. Department of Health and Human Services. https://www.cdc.gov/heart-disease/about/heart-failure.html Groenewegen, A., et al. (2020). Epidemiology of heart failure. European journal of heart failure, 22(8), 1342-1356. https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.1858 Redfield, M. M. (2016). Heart failure with preserved ejection fraction. New England Journal of Medicine, 375(19), 1868-1877. https://www.nejm.org/doi/full/10.1056/NEJMcp1511175 Chia, Y. C., et al. (2021). Interleukin 6 and development of heart failure with preserved ejection fraction in the general population. Journal of the American Heart Association, 10(11), e018549. https://www.ahajournals.org/doi/full/10.1161/JAHA.120.018549 Deswal, A., et al. (2001). Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation, 103(16), 2055-2059. https://www.ahajournals.org/doi/full/10.1161/01.CIR.103.16.2055 Murphy, S. P., et al. (2020). Inflammation in heart failure: JACC state-of-the-art review. Journal of the American College of Cardiology, 75(11), 1324-1340. https://www.jacc.org/doi/full/10.1016/j.jacc.2020.01.014 Fontes, J. A., et al. (2015). The varying faces of IL-6: From cardiac protection to cardiac failure. Cytokine, 74(1), 62-68. https://pmc.ncbi.nlm.nih.gov/articles/PMC4677779/ Abernethy, A., et al. (2018). Pro‐inflammatory biomarkers in stable versus acutely decompensated heart failure with preserved ejection fraction. Journal of the American Heart Association, 7(8), e007385. https://www.ahajournals.org/doi/full/10.1161/JAHA.117.007385 Paulus, W. J. (2020). Unfolding discoveries in heart failure. New England Journal of Medicine, 382(7), 679-682. https://www.nejm.org/doi/abs/10.1056/NEJMcibr1913825 Markousis‐Mavrogenis, G., et al. (2019). The clinical significance of interleukin‐6 in heart failure: results from the BIOSTAT‐CHF study. European journal of heart failure, 21(8), 965-973. https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.1482…

1
Short Circuits in the Heart: A Look at Atrial Fibrillation 5:06

7 weeks ago5:06

5:06

When the hot water went out, you might call a plumber, but if the water heater is out it might instead be an electrical problem - just like how heart problems can stem from faulty electrical signals rather than the heart muscle itself. Atrial fibrillation (AFib), the most common arrhythmia affecting six million Americans, disrupts the heart’s electrical system, causing rapid, chaotic beating that increases stroke risk fivefold. In this week's episode, we review AFib, the risk factors to develop it, symptoms , how it happens, and treatments. Water you waiting for, listen today! Share with a friend. Rate, Review, and Subscribe to MedEvidence! Articles to be notified when new episodes are released. Follow us on Social Media: Facebook Instagram Twitter LinkedIn Tiktok Youtube For more great content, including discussions by physicians and clinical research experts, check out the MedEvidence! podcast. www.MedEvidence.com Thank you for listening! References: Heijman, J., Voigt, N., N attel, S., & Dobrev, D. (2014). Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circulation research, 114 (9), 1483-1499. https://www.ahajournals.org/doi/full/10.1161/CIRCRESAHA.114.302226 Lip, G. Y., Fauchier, L., Freedman, S. B., Van Gelder, I., Natale, A., Gianni, C., ... & Lane, D. A. (2016). Atrial fibrillation (Primer). Nature Reviews: Disease Primers, 2 (1). https://www.proquest.com/scholarly-journals/atrial-fibrillation-primer/docview/2711094799/se-2?accountid=14690 Lloyd-Jones, D. M., Wang, T. J., Leip, E. P., Larson, M. G., Levy, D., Vasan, R. S., ... & Benjamin, E. J. (2004). Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation, 110 (9), 1042-1046. https://www.ahajournals.org/doi/full/10.1161/01.CIR.0000140263.20897.42 Munger, T.M., Wu, L.Q., Shen, W.K..(2013). Atrial fibrillation. J Biomed Res.28 (1):1-17. doi: 10.7555/JBR.28.20130191. https://pmc.ncbi.nlm.nih.gov/articles/PMC3904170/ Koren, M.J., & Sanghvi, N. (14 June, 2023). Two docs talk A-fib. On MedEvidence! Truth Behind the Data . [Podcast]. https://medevidence.com/two-docs-talk-a-fib-1 Wijesurendra, R. S., & Casadei, B. (2019). Mechanisms of atrial fibrillation. Heart, 105 (24), 1860-1867. https://heart.bmj.com/content/105/24/1860.abstract Yao, Y., Yang, M., Liu, D., & Zhao, Q. (2022). Immune remodeling and atrial fibrillation. Frontiers in Physiology, 13 , 927221. https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2022.927221/full…

1
The Heart is the Beat of Life 4:30

8 weeks ago4:30

4:30

This week's podcast is a crash course on what the heart is, why we need it, how it works, and what can go wrong. Share with a friend. Rate, Review, and Subscribe to MedEvidence! Articles to be notified when new episodes are released. Follow us on Social Media: Facebook Instagram Twitter LinkedIn Tiktok Youtube For more great content, including discussions by physicians and clinical research experts, check out the MedEvidence! podcast. www.MedEvidence.com Thank you for listening! References: D’souza, A., Wang, Y., Anderson, C., Bucchi, A., Baruscotti, M., Olieslagers, S., ... & Boyett, M. R. (2021). A circadian clock in the sinus node mediates day-night rhythms in Hcn4 and heart rate. Heart rhythm, 18(5), 801-810. https://pubmed.ncbi.nlm.nih.gov/33278629/ Betts, J. G., Young, A., Wise, J. A., Johnson, E., Poe, B., Kruse, D. H., Korol, O., Johnson, J. E., Womble, M., & DeSaix, P. (2013). 19.2 Cardiac muscle and electrical activity. In Anatomy and physiology . OpenStax. https://openstax.org/books/anatomy-and-physiology/pages/19-2-cardiac-muscle-and-electrical-activity Buckberg, G. D., Nanda, N. C., Nguyen, C., & Kocica, M. J. (2018). What is the heart? Anatomy, function, pathophysiology, and misconceptions. Journal of cardiovascular development and disease, 5(2) , 33. https://pmc.ncbi.nlm.nih.gov/articles/PMC6023278/ Chaudhry, R., Miao, J. H., & Rehman, A. (2022). Physiology, cardiovascular. In StatPearls [Internet] . StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK493197/ Hunter, P. J., Pullan, A. J., & Smaill, B. H. (2003). Modeling total heart function. Annual review of biomedical engineering , 5(1), 147-177. https://www.annualreviews.org/content/journals/10.1146/annurev.bioeng.5.040202.121537…

1
Alzheimer’s and ADHD, the Missing Link? 6:02

9 weeks ago6:02

6:02

This week we talk about two recent studies which suggest a potential link between adult ADHD and an increased risk of developing dementia; though causation remains unproven. These studies, one in Israel and another in Sweden, found that adults with ADHD were significantly more likely to develop dementia or mild cognitive impairment. These findings were consistent across most demographics, though ADHD medication appeared to reduce the risk. The research highlights the need for further exploration into shared mechanisms between these conditions and raises questions about whether ADHD may predispose the brain to dementia or if certain factors, such as psychiatric comorbidities or medication, play protective roles. Share with a friend. Rate, Review, and Subscribe to MedEvidence! Articles to be notified when new episodes are released. Follow us on Social Media: Facebook Instagram Twitter LinkedIn Tiktok Youtube For more great content, including discussions by physicians and clinical research experts, check out the MedEvidence! podcast. www.MedEvidence.com Thank you for listening! References: Callahan, B. L., Bierstone, D., Stuss, D. T., & Black, S. E. (2017). Adult ADHD: risk factor for dementia or phenotypic mimic?. Frontiers in Aging Neuroscience, 9 , 260. https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2017.00260/full Dobrosavljevic, M., Zhang, L., Garcia-Argibay, M., Du Rietz, E., Andershed, H., Chang, Z., ... & Larsson, H. (2022). Attention-deficit/hyperactivity disorder as a risk factor for dementia and mild cognitive impairment: A population-based register study. European Psychiatry, 65 (1), e3. https://pmc.ncbi.nlm.nih.gov/articles/PMC8792867/ Levine, S. Z., Rotstein, A., Kodesh, A., Sandin, S., Lee, B. K., Weinstein, G., ... & Reichenberg, A. (2023). Adult attention-deficit/hyperactivity disorder and the risk of dementia. JAMA network open, 6 (10), e2338088-e2338088. https://pmc.ncbi.nlm.nih.gov/articles/PMC10582792/ Moffitt, T. E., Houts, R., Asherson, P., Belsky, D. W., Corcoran, D. L., Hammerle, M., ... & Caspi, A. (2015). Is adult ADHD a childhood-onset neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort study. American Journal of Psychiatry, 172 (10), 967-977. https://psychiatryonline.org/doi/full/10.1176/appi.ajp.2015.14101266 Yokoi, T. (2023). Alzheimer’s Disease is a Disorder of Consciousness. Gerontology and Geriatric Medicine, 9 , 23337214231159759. https://pmc.ncbi.nlm.nih.gov/articles/PMC9989409/…

1
Shiny Legs, Hidden Danger 6:21

9 weeks ago6:21

6:21

This week we discuss peripheral artery disease (PAD), a condition affecting blood flow in the peripheral arteries, most commonly in the legs. We cover its symptoms, such as leg pain, skin changes, and slow-healing wounds, as well as the potential risks of untreated PAD, including amputation and cardiovascular complications. We then talk about treatment options, including medications, lifestyle changes, structured exercise programs, and advanced interventions like revascularization. Share with a friend. Rate, Review, and Subscribe to MedEvidence! Articles to be notified when new episodes are released. Follow us on Social Media: Facebook Instagram Twitter LinkedIn Tiktok Youtube For more great content, including discussions by physicians and clinical research experts, check out the MedEvidence podcast. www.MedEvidence.com Thank you for listening! References: Golledge, J. (2022). Update on the pathophysiology and medical treatment of peripheral artery disease. Nature reviews cardiology, 19(7) , 456-474. https://www.nature.com/articles/s41569-021-00663-9 Allison, M. A., Ho, E., Denenberg, J. O., Langer, R. D., Newman, A. B., Fabsitz, R. R., & Criqui, M. H. (2007). Ethnic-specific prevalence of peripheral arterial disease in the United States. American journal of preventive medicine , 32(4), 328-333. https://www.sciencedirect.com/science/article/pii/S0749379706005587 Dean, S. M. (2018). Cutaneous manifestations of chronic vascular disease. Progress in Cardiovascular Diseases, 60(6) , 567-579. https://www.sciencedirect.com/science/article/pii/S0033062018300549?via=ihub Fowkes, F. G. R., Aboyans, V., Fowkes, F. J., McDermott, M. M., Sampson, U. K., & Criqui, M. H. (2017). Peripheral artery disease: epidemiology and global perspectives. Nature Reviews Cardiology, 14(3), 156-170. https://www.nature.com/articles/nrcardio.2016.179 Gerhard-Herman, M. D., Gornik, H. L., Barrett, C., Barshes, N. R., Corriere, M. A., Drachman, D. E., ... & Walsh, M. E. (2017). 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation , 135(12), e686-e725. https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000470 Related Reading Umuerri, E. M. (2019). Skin manifestations of peripheral artery disease: Prevalence and diagnostic utility. Journal of Clinical and Preventive Cardiology , 8 (3), 121-125. https://journals.lww.com/jcpc/fulltext/2019/08030/skin_manifestations_of_peripheral_artery_disease_.3.aspx…

1
Is the Deadliest Condition Preventable? Understanding ASCVD and LDL-C 5:40

10 weeks ago5:40

5:40

This episode explores atherosclerotic cardiovascular disease (ASCVD), the leading cause of heart attacks and strokes worldwide. Learn about the role of LDL cholesterol in the development of fatty plaques that harden and block blood vessels, as well as the risks associated with ASCVD, including heart disease and peripheral artery disease. The episode highlights preventive strategies such as healthy lifestyle changes and treatments like statins, PCSK9 inhibitors, and emerging clinical trial therapies. Discover how understanding and managing LDL cholesterol levels can help reduce the burden of this preventable yet most deadly condition. Share with a friend. Rate, Review, and Subscribe to MedEvidence Articles to be notified when new episodes are released. Follow us on Social Media: Facebook Instagram Twitter LinkedIn Tiktok Youtube For more great content, including discussions by physicians and clinical research experts, check out the MedEvidence! podcast. www.MedEvidence.com Thank you for listening! References: Makover, M. E., Shapiro, M. D., & Toth, P. P. (2022). There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness. American Journal of Preventive Cardiology, 12, 100371. https://pmc.ncbi.nlm.nih.gov/articles/PMC9482082/ World Health Organization. (7 August, 2024). The top 10 causes of death. [website]. Accessed 16 December, 2024. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death Ference, B. A., et al. (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European heart journal, 38(32), 2459-2472. https://academic.oup.com/eurheartj/article/38/32/2459/3745109 Ferhatbegović, L., Mršić, D., Kušljugić, S., & Pojskić, B. (2022). LDL-C: the only causal risk factor for ASCVD. Why is it still overlooked and underestimated?. Current Atherosclerosis Reports, 24(8), 635-642. https://link.springer.com/article/10.1007/s11883-022-01037-3 Mundi, S., et al. (2018). Endothelial permeability, LDL deposition, and cardiovascular risk factors—A review. Cardiovascular research, 114(1), 35-52. https://pmc.ncbi.nlm.nih.gov/articles/PMC7729208/ Jebari-Benslaiman, S., et al. (2022). Pathophysiology of atherosclerosis. International journal of molecular sciences, 23(6), 3346. https://www.mdpi.com/1422-0067/23/6/3346 Arnett, D. K., et al. (2019). 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of cardiology, 74(10), e177-e232. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000678…

1
From Trials to Triumph: 2024’s FDA approvals 7:12

10 weeks ago7:12

7:12

Join us this week for a brief tour of some body systems as we review five medications approved by the FDA in 2024. From liver disease to Alzheimer’s, we look at Rezdiffra, Iqirvo, Vafseo, Entyvio, and Kisunla, exploring the diseases they intend to treat and a brief overview of how the medicines work. We celebrate the hard work of volunteers, investigators, coordinators, and other participants in the clinical trial process. Share with a friend. Rate, Review, and Subscribe to MedEvidence! Articles to be notified when new episodes are released. Follow us on Social Media: Facebook Instagram Twitter LinkedIn Tiktok Youtube For more great content, including discussions by physicians and clinical research experts, check out the MedEvidence! podcast. www.MedEvidence.com Thank you for listening! References: Akebia Therapeutics, Inc. (27 March, 2024). Akebia receives FDA approval of Vafseo®... PR Newswire. Link Chertow, G. M. et al. (2021). Vadadustat in patients with anemia... New England Journal of Medicine, 384(17), 1589-1600. Link Harrison, S. A. et al. (2024). A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. New England Journal of Medicine, 390(6), 497-509. Link Ipsen. (10 June, 2024). Ipsen’s Iqirvo® receives U.S. FDA accelerated approval... Link Jayaprakash, N., & Elumalai, K. (2024). Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application. Chronic Diseases and Translational Medicine. Link Kowdley, K. V. et al. (2024). Efficacy and safety of elafibranor in primary biliary cholangitis. New England Journal of Medicine, 390(9), 795-805. Link Madrial Pharmaceuticals, Inc. (14 March, 2024). Madrigal pharmaceuticals announces FDA approval of Rezdiffra™... Link Takeda. (18 April, 2024). U.S. FDA approves subcutaneous administration of Takeda’s ENTYVIO®... Link U.S. Food and Drug Administration. (7 January, 2025). Novel Drug Approvals for 2024. Link Wyant, T., et al. (2016). An overview of the mechanism of action of the monoclonal antibody vedolizumab. Journal of Crohn's and Colitis, 10(12), 1437-1444. Link…

1
Shedding Light on Seasonal Depression 5:10

11 weeks ago5:10

5:10

In this episode, we delve into the complexities of Seasonal Affective Disorder (SAD), a subtype of Major Depressive Disorder that fluctuates with the seasons. Seasonal Affective Disorder, a condition affecting millions during the darker months. We explore its symptoms, causes, and demographic prevalence, highlighting its impact on mood, cognition, and physical health. The episode also examines leading theories behind SAD, such as disruptions in circadian rhythms and hormonal imbalances linked to reduced sunlight exposure, and the biological underpinnings. We then move to existing treatment options, including light therapy and cognitive behavioral therapy. With limited clinical trials, the episode underscores the importance of advancing research into effective interventions. Share with a friend. Rate, Review, and Subscribe to MedEvidence! Articles to be notified when new episodes are released. Follow us on Social Media: Facebook Instagram Twitter LinkedIn Tiktok Youtube For more great content, including discussions by physicians and clinical research experts, check out the MedEvidence! podcast. www.MedEvidence.com Thank you for listening! References: American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Munir, S., Gunturu, S., & Abbas, M. (20 April, 2024). Seasonal Affective Disorder. StatPearls [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK568745/ Dang, T., Russel, W. A., Saad, T., Dhawka, L., Ay, A., & Ingram, K. K. (2023). Risk for Seasonal Affective Disorder (SAD) Linked to Circadian Clock Gene Variants. Biology, 12(12), 1532. https://www.mdpi.com/2079-7737/12/12/1532 National Institute of Mental Health. (2023). Seasonal Affective Disorder (NIH Publication No. 23-MH-8138). U.S. Department of Health and Human Services, National Institutes of Health. https://www.nimh.nih.gov/health/publications/seasonal-affective-disorder Willeit, M., Sitte, H. H., Thierry, N., Michalek, K., Praschak-Rieder, N., Zill, P., ... & Singer, E. A. (2008). Enhanced serotonin transporter function during depression in seasonal affective disorder. Neuropsychopharmacology, 33(7), 1503-1513. https://www.nature.com/articles/1301560 National Library of Medicine. (n.d.). Search for: seasonal affective disorder, in United States. ClinicalTrials.gov [Website] https://clinicaltrials.gov/search?locStr=United%20States&country=United%20States&cond=Seasonal%20Affective%20Disorder Dumville, J. C., Miles, J. N. V., Porthouse, J., Cockayne, S., Saxon, L., & King, C. (2006). Can vitamin D supplementation prevent winter-time blues? A randomised trial among older women. Journal of Nutrition Health and Aging, 10(2), 151. https://pubmed.ncbi.nlm.nih.gov/16554952/ Frandsen, T. B., Pareek, M., Hansen, J. P., & Nielsen, C. T. (2014). Vitamin D supplementation for treatment of seasonal affective symptoms in healthcare professionals: a double-blind randomised placebo-controlled trial. BMC research notes, 7, 1-8. https://pmc.ncbi.nlm.nih.gov/articles/PMC4141118/ Harris, S., & Dawson-Hughes, B. (1993). Seasonal mood changes in 250 normal women. Psychiatry research, 49(1), 77-87. https://pubmed.ncbi.nlm.nih.gov/8140183/ Jorde, R., Sneve, M., Figenschau, Y., Svartberg, J., & Waterloo, K. (2008). Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial. Journal of internal medicine, 264(6), 599-609. https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2796.2008.02008.x…

1
Migraine vs. Komodo Dragon: A Battle of Headache Proportions 5:58

12 weeks ago5:58

5:58

This week we discuss episodic and chronic migraines. Migraines are primary headaches that affect about a billion people globally each year. In this weeks episode, we discuss symptoms and the differences between episodic and chronic migraines. Learn about risk factors, treatment options, and why accurate and appropriate treatment is critical to keep episodic migraines from getting worse. Share with a friend. Rate, Review, and Subscribe to MedEvidence Articles to be notified when new episodes are released. Follow us on Social Media: Facebook Instagram Twitter LinkedIn Tiktok Youtube For more great content, including discussions by physicians and clinical research experts, check out the MedEvidence! podcast. www.MedEvidence.com Thank you for listening! References: Safiri, S., et al. (2022). Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. Pain, 163(2), e293-e309. https://oce.ovid.com/article/00006396-202202000-00028/HTML International Headache Society. (2018). 1. Migraine. IHS Classification ICHD-3. https://ichd-3.org/1-migraine/ Koren, M.J. & Toenjes, S. (Hosts). (2024). Two docs talk: Migraines. [Podcast Episode]. In MedEvidence! Truth Behind the Data. MedEvidence. https://medevidence.com/two-docs-talk-migraines May, A., & Schulte, L. H. (2016). Chronic migraine: risk factors, mechanisms and treatment. Nature Reviews Neurology, 12(8), 455-464. https://www.nature.com/articles/nrneurol.2016.93 Young, N. P., et al. (2019). Episodic and chronic migraine in primary care. Headache: The Journal of Head and Face Pain, 59(7), 1042-1051. https://doi.org/10.1111/head.13543 Schürks, M., et al. (2009). Migraine and cardiovascular disease: systematic review and meta-analysis. Bmj, 339. https://www.bmj.com/content/339/bmj.b3914 Amiri, P., et al. (2022). Migraine: a review on its history, global epidemiology, risk factors, and comorbidities. Frontiers in neurology, 12, 800605. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2021.800605/full Bigal, M. E., et al. (2008). Acute migraine medications and evolution from episodic to chronic migraine: A longitudinal population‐based study. Headache: The Journal of Head and Face Pain, 48(8), 1157-1168. https://doi.org/10.1111/j.1526-4610.2008.01217.x Mathew, N. T., Kurman, R., & Perez, F. (1990). Drug induced refractory headache‐clinical features and management. Headache: The Journal of Head and Face Pain, 30(10), 634-638. https://doi.org/10.1111/j.1526-4610.1990.hed3010634.x Lipton, R. B., & Silberstein, S. D. (2015). Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache: The Journal of Head and Face Pain, 55, 103-122. https://doi.org/10.1111/head.12505_2…

1
No Gym, No Problem: Making Fitness Work for You 6:22

13 weeks ago6:22

6:22

This podcast episode examines the challenges of sticking to fitness resolutions and how to make exercise more accessible and sustainable. We discuss the health benefits of physical activity, the impact of stress on the body, and why reducing barriers like time, cost, and convenience can improve consistency. Learn practical tips for incorporating fitness into your routine, including effective home-based exercises and strategies to stay motivated throughout the year. Share with a friend. Rate, Review, and Subscribe to MedEvidence Articles to be notified when new episodes are released. Follow us on Social Media: Facebook Instagram Twitter LinkedIn Tiktok Youtube For more great content, including discussions by physicians and clinical research experts, check out the MedEvidence podcast. www.MedEvidence.com Thank you for listening! References: Mastorakos, G., Pavlatou, M., Diamanti-Kandarakis, E., & Chrousos, G. P. (2005). Exercise and the stress system. Hormones (Athens), 4(2), 73-89. https://europepmc.org/article/med/16613809 Raghuveer, G., et al. (2020). Cardiorespiratory fitness in youth: an important marker of health: a scientific statement from the American Heart Association. Circulation, 142(7), e101-e118. https://pmc.ncbi.nlm.nih.gov/articles/PMC7524041/ Mangine, G. T., et. al. (2017). Exercise-induced hormone elevations are related to muscle growth. The Journal of Strength & Conditioning Research, 31(1), 45-53. https://journals.lww.com/nsca-jscr/fulltext/2017/01000/Exercise_Induced_Hormone_Elevations_Are_Related_to.6.aspx Kivimäki, M., & Steptoe, A. (2018). Effects of stress on the development and progression of cardiovascular disease. Nature Reviews Cardiology, 15(4), 215-229. https://www.nature.com/articles/nrcardio.2017.189 Pescatello, L. S., Franklin, B. A., Fagard, R., Farquhar, W. B., Kelley, G. A., & Ray, C. A. (2004). Exercise and hypertension. Medicine & science in sports & exercise, 36(3), 533-553. https://europepmc.org/article/med/15076798 Kokkinos, P., Faselis, C., Samuel, I. B. H., Lavie, C. J., Zhang, J., Vargas, J. D., ... & Myers, J. (2023). Changes in cardiorespiratory fitness and survival in patients with or without cardiovascular disease. Journal of the American college of cardiology, 81(12), 1137-1147. https://www.jacc.org/doi/10.1016/j.jacc.2023.01.027 Koren, MJ., Geddings, K. (27 March, 2023). Research of exercise. [Audio Recording]. In MedEvidence! Truth Behind the Data. MedEvidence. https://medevidence.com/research-of-exercise Further Reading Argent, R., Daly, A., & Caulfield, B. (2018). Patient involvement with home-based exercise programs: can connected health interventions influence adherence?. JMIR mHealth and uHealth, 6(3), e8518. https://pmc.ncbi.nlm.nih.gov/articles/PMC5856927/…

1
Will the Science of Exosomes Revolutionize Medicine? 5:24

14 weeks ago5:24